- In July 2024, Amvia Sky introduced the Amvia Sky HF-T QP pacemaker in Canada, which features a variety of advanced capabilities, including atrial arrhythmia management tools, CRT AutoAdapt, streamlined care pathways, next-generation MRI access with 24/7 MRI Guard, and 20 left ventricular pacing polarities
- In June 2024, Boston Scientific launched the HiRes Ultra 3D, an innovative cochlear implant aimed at enhancing hearing for individuals with severe hearing loss. This next-generation device utilizes advanced sound processing technology to provide clearer audio quality and a more natural listening experience, particularly benefiting the aging population that frequently suffers from hearing impairments
- In April 2024, Abbott Laboratories unveiled its newest cardiac implantable device, the Confirm Rx+, which monitors heart rhythms and alerts patients to any irregularities. This revolutionary device is the first of its kind to integrate with smartphone technology, allowing real-time data sharing with healthcare providers. Given the increasing incidence of cardiac diseases globally, the Confirm Rx+ is poised to improve patient engagement and outcomes through timely interventions
- In March 2024, Medtronic announced the introduction of an advanced neurostimulator designed to manage chronic pain more effectively. This new device boasts wireless charging capabilities for extended battery life and enhanced patient comfort. It also features sophisticated algorithms that adjust therapy based on the patient's activity levels, promising improved pain relief outcomes and addressing the demand for less invasive treatment solutions
- In February 2024, Johnson & Johnson MedTech launched the Tecnis Puresee Intraocular Lens (IOL) across Europe, the Middle East, and Africa (EMEA)
- In November 2022, Cochlear Limited announced FDA approval for its Cochlear Nucleus 8 Sound Processor, which incorporates innovative technology that automatically adjusts its listening settings based on changes in the user's environment, thereby enhancing the overall user experience
Frequently Asked Questions
The market is segmented based on Segmentation, By Product (Pacemakers & Defibrillators, Neurostimulators, Implantable Drug Pumps, and Spinal Fusion Stimulators), Application (Cardiology, Neurology, Ophthalmology, Oncology, and Others), Material (Metals, Polymers, and Ceramics) – Industry Trends and Forecast to 2031
.
The Global Microelectronic Medical Implants Market size was valued at USD 6.12 USD Billion in 2023.
The Global Microelectronic Medical Implants Market is projected to grow at a CAGR of 4.21% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
